Tenecteplase for Acute Ischemic Stroke: Current Evidence and Practical Considerations

Alejandro A. Rabinstein, Esteban Golombievski, Jose Biller

Research output: Contribution to journalArticlepeer-review


Tenecteplase offers pharmacological advantages over alteplase, and growing evidence supports its consideration for the treatment of patients with acute ischemic stroke. Its ease of administration as a single bolus makes it a preferable agent for patients who need to be urgently transported to a comprehensive stroke center for endovascular therapy (drip and ship) and for patients first evaluated at comprehensive stroke centers who are eligible for endovascular intervention (combined intravenous and endovascular approach). Recent randomized controlled trials indicated that the efficacy of tenecteplase may be similar to that of alteplase in patients with mild strokes and that it is superior to alteplase for patients with more severe strokes from a large vessel occlusion. Cumulative evidence currently favors the use of the 0.25 mg/kg dose. While tenecteplase has not been approved by regulatory agencies in the USA or the EU for the treatment of acute ischemic stroke, ongoing trials and additional clinical experience from countries where it is already being used in practice will likely clarify the role of tenecteplase for the acute management of ischemic stroke in the near future.

Original languageEnglish (US)
Pages (from-to)1009-1014
Number of pages6
JournalCNS Drugs
Issue number10
StatePublished - Oct 1 2020

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Tenecteplase for Acute Ischemic Stroke: Current Evidence and Practical Considerations'. Together they form a unique fingerprint.

Cite this